HIRmAb-GDNF does not induce improve parkinsonian signs and is associated with type I hypersensitivity reaction.

(A) Clinical rating score. (B) Fine motor skills task. (C) Hypersensitivity response over time, by treatment group. (D) Optical density (OD) of HIRmAb-GDNF antibody levels in serum.